• MDxHealth posted revenue of $51.11 million for the six months ended June 30, 2026, up 14%.
• Operating loss more than doubled to $13.26 million as operating expenses climbed 25% to $45.82 million.
• Net loss from continuing operations widened 18% to $19.17 million; loss per share from continuing operations deepened to $0.37.
• Gross profit rose 7% to $32.56 million; gross margin fell 4.2 percentage points to 63.7% on test mix.
• Resolve UTI business was discontinued by June 30, 2026; August direct placement raised $20 million at $0.45 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-097170), on September 03, 2026, and is solely responsible for the information contained therein.